Viral Vector And Plasmid DNA Testing Services Market

Viral Vector And Plasmid DNA Testing Services Market, By Service Type (Safety, Genetic Characterization, Purity, Identity and Potency), By End User (Pharmaceutical and Biotechnology Industries and Research Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Testing services are crucial for the timely development of viral vector-based medicines since viral vectors are the best strategy for gene therapies. Characterization of the viral vector plays an essential role for orthogonal analytical methods. Through the regulatory prospective which includes product safety, identification, purity, and potency, the characterization is significant. These days, viral vectors are the primary delivery system for a variety of virus-based medications that have been created for various therapies for conditions including cancer, neurology, hematology, ophthalmology, metabolic or muscular disorders and are accepted on the global market. The pharmaceutical industry has a bright future for several developments based on viral-based medicines.

Market Dynamics

The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, in October, 2022, ICON plc, a clinical research organization, in collaboration with researchers from Imam Abdulrahman Bin Faisal University, based in Saudi Arabia, announced the initiation of Phase-I clinical trial Study to Evaluate the Safety and Immunogenicity of 2 or 3 dose regimen of investigational Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults. The pDNA vaccine candidate is administered intramuscularly (IM) by immunizing healthy adults (18-55 years).

Similarly, in January 2022, GeneOne Life Science, Inc., a biotechnology company, in collaboration with Inovio Pharmaceuticals, a biotechnology company, announced initiation of clinical trial to assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus, which is currently in Phase -1.

Key features of the study:This report provides in-depth analysis of the global viral vector and plasmid DNA testing services market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base yearIt elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this marketThis study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key playersIt profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategiesKey companies covered as a part of this study are Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KgaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, Genezen Laboratories, Akron Biotech., Catalent, Inc, AcuraBio., CATUG Biotechnology., Creative Biogene and AldevronInsights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tacticsGlobal viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analystsStakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA testing services marketDetailed Segmentation:Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type:SafetyGenetic CharacterizationPurityIdentityPotencyGlobal Viral Vector and Plasmid DNA Testing Services Market By End User:Pharmaceutical and Biotechnology IndustriesResearch OrganizationsGlobal Viral Vector and Plasmid DNA Testing Services Market, By Region:North AmericaU.S.CanadaLatin AmericaBrazilMexicoArgentinaRest of Latin AmericaEuropeGermanyU.K.FranceItalySpainRussiaRest of EuropeAsia PacificChinaIndiaJapanAustraliaSouth KoreaASEANRest of Asia PacificMiddle EastGCCIsraelRest of Middle EastAfricaSouth AfricaCentral AfricaNorth AfricaCompany ProfilesCharles River Laboratories, Inc.WuXi AppTec Co., Ltd.Cobra Biologics and Pharmaceutical ServicesMerck KgaALonzaEurofins ScientificFinVector Vision TherapiesAdvanced Bioscience Laboratories, Inc.Takara Bio Inc.ViruSure GmbHGenezen LaboratoriesAkron Biotech.Catalent, IncAcuraBioCATUG Biotechnology.Creative Biogene.Aldevron